R&D
Technology to Increase Selectivity for
cancer cells and Enhance Efficacy
NTX-101
  • HOME
  • R&D
  • NTX-101

Eye Drops for Glaucoma

NTX-101 is the first-in-class eye drops that inhibit the activity of the well-established target 11β-HSD1 by simultaneously lowering intraocular pressure and protecting the optic nerve.
NTX-101 is being developed as a therapy for glaucoma.

NTX-101 Mechanism of Action

Inhibition of the cortisol concentrator 11β-HSD1 confers direct optic nerve protection

Clinical trial status

Project Indication Development Stage

Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Clinical Site
NTX-101 Glaucoma
- KR Phase 1(finished)